Navigation Links
Sinapis Pharma Closes Series 'A' Financing
Date:11/17/2009

JACKSONVILLE, Fla., Nov. 17 /PRNewswire/ -- Sinapis Pharma, Inc. has successfully completed a Series "A" Preferred stock offering that has raised $510,000 for its ongoing drug development program. Sinapis Pharma has discovered and is developing a novel therapeutic approach to neuronal protection using its intravenous methamphetamine technology. The company has strong pre-clinical data in stroke and traumatic brain injury animal models conclusively demonstrating a 12-hour therapeutic window and multiple pathway neuroprotection.

The current financing will allow the company to reach significant development milestones. Investigational New Drug (IND) application submission to the FDA is anticipated for December 2009 with a Phase I clinical trial commencing in the first quarter of 2010. A Phase II proof of concept study is expected to commence in late 2010 for the stroke indication in humans.

Dr. Donald Picker, Sinapis CEO, relates: "We are excited that we can begin the development of methamphetamine for stroke. We have a rapid, inexpensive development pathway to proof of principle in man within 24 months due to the drug's previous human use for other indications, and anticipate being the first drug to enter stroke clinical trials with solid 6-12 hour pre-clinical data."

Sinapis Pharma, Inc. (www.sinapispharma.com) is an early stage biotechnology company whose lead compound methamphetamine, as a low-dose intravenous infusion, has shown remarkable pre-clinical efficacy in stroke and brain injury models.

For more information contact Dr. Picker at Don.Picker@gmail.com.

SOURCE Sinapis Pharma, Inc.


'/>"/>
SOURCE Sinapis Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... May 5, 2016 ... the  "Europe Systemic Lupus Erythematosus Market and ... their offering.       (Logo: ... research Europe Systemic Lupus Erythematosus Market and ... insights into Systemic Lupus Erythematosus pipeline products, ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 /PRNewswire/ ... announced today that BiondVax,s CEO, Dr. Ron Babecoff , ... New York City . On ... at Pioneers 2016, a conference presented by Joseph Gunner ... Hotel. The BiondVax presentation that Dr. Babecoff will ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... (PRWEB) May 05, 2016 , ... Talent Tech Labs ... HireNurses, on the eve of National Nurses Week (May 6-12). Currently, HireNurses ... employers. With their enrollment into the Talent Tech Lab Virtual Incubation program, they will ...
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, yet dangerous, ... the immune system and increase inflammation, both of which raise the risk of heart ... heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead to ...
(Date:5/5/2016)... Dallas, Texas (PRWEB) , ... May 05, 2016 ... ... and relationship-marketing firm, honored finalists and winners Tuesday evening, May 3, at the ... Dallas, Texas. , Scott Pettigrew, Vice President and Chief Security Officer of ...
(Date:5/5/2016)... , ... May 05, 2016 , ... If you don’t ... marks on your skin, you may want to consider a treatment that some have ... Advanced Dermatology P.C. , Microneedling, also known as skin needling, is a ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pigment Laser Tattoo Removal Center is proud to ... new PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. This ... laser on the market. Jeremy Miller, Tattoo Artist and former reality show contestant ...
Breaking Medicine News(10 mins):